Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: May 6, 2003
Last updated: July 17, 2013
Last verified: July 2004
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2004
  Estimated Primary Completion Date: No date given